Accel Wealth Management Aurinia Pharmaceuticals Inc. Transaction History

Accel Wealth Management

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 26, 2023	SELL	$4.11 - $8.14 $27,989 - $55,433	-6,810 Reduced 86.7%	1,045 $0
Q3 2022 Oct 12, 2022	BUY	$6.66 - $12.39 $49,084 - $91,314	7,370 Added 1519.59%	7,855 $59,000
Q4 2021 Jan 18, 2022	BUY	$17.78 - $33.08 $2,400 - $4,465	135 Added 38.57%	485 $11,000
Q3 2021 Nov 04, 2021	SELL	$10.93 - $23.55 $17,870 - $38,504	-1,635 Reduced 82.37%	350 $8,000
Q2 2021 Aug 03, 2021	BUY	$10.0 - $14.52 $15,000 - $21,780	1,500 Added 309.28%	1,985 $26,000
Q4 2020 Jan 27, 2021	BUY	$12.94 - $16.05 $6,275 - $7,784	485 New	485 $7,000

208

58.1M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.14B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Accel Wealth Management, based on Form 13F filings with the SEC.

Stay updated on Accel Wealth Management with notifications on news.